Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received ...

Goldman Sachs initiated coverage of 89bio (ETNB) with a Neutral rating and $11 price target 89bio is a late-stage clinical company focused on ...

Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigation ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis ...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitorFirst-in-human Phase 1 trial initiation planned in 2025SAN MATEO, Calif., ...

Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), ...

Activity (necroinflammation) and fibrosis are two major histologic features of chronic hepatitis C included in different proposed classifications. One of the few validated scoring systems is ...

Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis ...

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...